Clinical Performance of Duritect‐AD <sup>TM</sup> : a Blood‐based Autoantibody Test for the Detection of Alzheimer's Disease‐Related Pathology
Duritect-AD<sup>TM</sup> is a CLIA/CAP validated blood-based autoantibody test for the assessment of the risk of AD-related pathology in patients aged 55 and older presenting in primary care settings with signs or symptoms of cognitive impairment that could indicate suspected AD. Duritect-AD<sup>TM</sup> is an accurate, minimally invasive, and inexpensive test that can be used to aid in the detection of early, AD-related pathology associated with prodromal (MCI) and later stages of AD.
Authors
- Jeffrey Viviano (ORCID: https://orcid.org/0000-0003-2006-5306)
- Robert G. Nagele (ORCID: https://orcid.org/0000-0003-2691-4137)
- Cassandra DeMarshall
- Anuradha Krishnan (ORCID: https://orcid.org/0000-0001-9401-0776)
- Mert Sahin
- Funda Suer
Institutions
- Stratford University (US)
- Rowan University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_100979
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00